Nov. 5 at 9:20 AM
$ENSC Our proprietary TAAP™ (Trypsin-Activated Abuse Protection) platform, which has received FDA Fast Track designation, has the potential to redefine opioid safety.
Unlike traditional abuse-deterrent formulations, TAAP™ opioids are only activated by trypsin, a digestive enzyme found in the gut, making them resistant to manipulation by crushing, chewing, snorting, or injection.
With a two-step activation process and 12+ hours of pain relief, TAAP™ aims to deliver effective treatment while minimizing the risk of misuse and abuse.
This breakthrough technology represents a major step forward in developing safer pain therapies for those with severe pain while addressing the opioid crisis through innovation.
